Literature DB >> 28960581

Inhibitory motor dysfunction in parkinson's disease subtypes.

Tao Gong1, Yuanyuan Xiang2, Muhammad G Saleh3,4, Fei Gao1, Weibo Chen5, Richard A E Edden3,4, Guangbin Wang1.   

Abstract

BACKGROUND: Parkinson's disease (PD) is divided into postural instability gait difficulty (PIGD) and tremor-dominant (TD) subtypes. Increasing evidence has suggested that the GABAergic neurotransmitter system is involved in the pathogenesis of PD.
PURPOSE: To evaluate the differences of GABA levels between PD motor subtypes using MEscher-GArwood Point Resolved Spectroscopy (MEGA-PRESS). STUDY TYPE: COHORT.:
SUBJECTS: PD patients were classified into PIGD (n = 13) and TD groups (n = 9); 16 age- and sex-matched healthy controls were also recruited. All subjects were right-handed. SEQUENCE: All subjects underwent an magnetic resonance spectroscopy scan including MEGA-PRESS at 3.0T. ASSESSMENT: The detected GABA signal also contains signal from macromolecules (MM) and homocarnosine, so it is referred to as GABA+. GABA + levels and Creatine (Cr) levels were quantified in the left basal ganglia (BG) using Gannet 2.0 by Tao Gong. STATISTICAL TESTS: Differences in GABA + levels between the three groups were analyzed using analysis of covariance. The relationship between GABA levels and a unified PD rating scale (UPDRS) was also analyzed.
RESULTS: GABA + levels were significantly lower in left BG regions of PD patients compared with healthy controls (P < 0.001). In PD patients, the GABA concentration was lower in the TD group than the PIGD group (P = 0.019). Cr levels in PIGD and TD were lower than controls (P = 0.020; P = 0.002). A significant negative correlation was found in PIGD between GABA levels and UPDRS (r = -0.572, P = 0.041), while no correlation was found in TD (r = -0.339, P = 0.372). DATA
CONCLUSION: Low BG GABA levels in PD patients, and differences between PIGD/TD patients, suggest that GABAergic dysfunction may play an important role in the pathogenesis of Parkinson's disease. LEVEL OF EVIDENCE: 1 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:1610-1615.
© 2017 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  GABA; MEGA-PRESS; Parkinson's disease; postural instability gait difficulty; tremor

Mesh:

Substances:

Year:  2017        PMID: 28960581      PMCID: PMC5871546          DOI: 10.1002/jmri.25865

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  37 in total

1.  NMR relaxation times in the human brain at 3.0 tesla.

Authors:  J P Wansapura; S K Holland; R S Dunn; W S Ball
Journal:  J Magn Reson Imaging       Date:  1999-04       Impact factor: 4.813

2.  (1)H-MRS and MEGA-PRESS pulse sequence in the study of balance of inhibitory and excitatory neurotransmitters in the human brain of ultra-high risk of schizophrenia patients.

Authors:  P E Menschikov; N A Semenova; M V Ublinskiy; T A Akhadov; R A Keshishyan; I S Lebedeva; M A Omelchenko; V G Kaleda; S D Varfolomeev
Journal:  Dokl Biochem Biophys       Date:  2016-07-15       Impact factor: 0.788

3.  Prospective frequency correction for macromolecule-suppressed GABA editing at 3T.

Authors:  Richard A E Edden; Georg Oeltzschner; Ashley D Harris; Nicolaas A J Puts; Kimberly L Chan; Vincent O Boer; Michael Schär; Peter B Barker
Journal:  J Magn Reson Imaging       Date:  2016-05-30       Impact factor: 4.813

Review 4.  Nigrostriatal interaction in the aging brain: new therapeutic target for Parkinson's disease.

Authors:  Janusz W Błaszczyk
Journal:  Acta Neurobiol Exp (Wars)       Date:  2017       Impact factor: 1.579

5.  A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome.

Authors:  M Gerlach; W Gsell; J Kornhuber; K Jellinger; V Krieger; F Pantucek; R Vock; P Riederer
Journal:  Brain Res       Date:  1996-11-25       Impact factor: 3.252

6.  Comparison of T(1) and T(2) metabolite relaxation times in glioma and normal brain at 3T.

Authors:  Yan Li; Radhika Srinivasan; Helene Ratiney; Ying Lu; Susan M Chang; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2008-08       Impact factor: 4.813

7.  Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.

Authors:  S J Kish; A Rajput; J Gilbert; B Rozdilsky; L J Chang; K Shannak; O Hornykiewicz
Journal:  Ann Neurol       Date:  1986-07       Impact factor: 10.422

8.  Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS.

Authors:  Uzay E Emir; Paul J Tuite; Gülin Öz
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

9.  Changes in GABA and glutamate concentrations during memory tasks in patients with Parkinson's disease undergoing DBS surgery.

Authors:  Robert J Buchanan; David P Darrow; Kevin T Meier; Jennifer Robinson; Dawn M Schiehser; David C Glahn; Zoltan Nadasdy
Journal:  Front Hum Neurosci       Date:  2014-03-07       Impact factor: 3.169

10.  Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis.

Authors:  Janusz W Błaszczyk
Journal:  Front Neurosci       Date:  2016-06-09       Impact factor: 4.677

View more
  8 in total

Review 1.  Using Caenorhabditis elegans to Model Therapeutic Interventions of Neurodegenerative Diseases Targeting Microbe-Host Interactions.

Authors:  Chenyin Wang; Chaogu Zheng
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

Review 2.  Edited magnetic resonance spectroscopy in the neonatal brain.

Authors:  Yulu Song; Peter J Lally; Maria Yanez Lopez; Georg Oeltzschner; Mary Beth Nebel; Borjan Gagoski; Steven Kecskemeti; Steve C N Hui; Helge J Zöllner; Deepika Shukla; Tomoki Arichi; Enrico De Vita; Vivek Yedavalli; Sudhin Thayyil; Daniele Fallin; Douglas C Dean; P Ellen Grant; Jessica L Wisnowski; Richard A E Edden
Journal:  Neuroradiology       Date:  2021-10-15       Impact factor: 2.995

3.  Multi-vendor standardized sequence for edited magnetic resonance spectroscopy.

Authors:  Muhammad G Saleh; Daniel Rimbault; Mark Mikkelsen; Georg Oeltzschner; Anna M Wang; Dengrong Jiang; Ali Alhamud; Jamie Near; Michael Schär; Ralph Noeske; James B Murdoch; Lars Ersland; Alexander R Craven; Gerard Eric Dwyer; Eli Renate Grüner; Li Pan; Sinyeob Ahn; Richard A E Edden
Journal:  Neuroimage       Date:  2019-01-22       Impact factor: 6.556

4.  GSH and GABA decreases in IDH1-mutated low-grade gliomas detected by HERMES spectral editing at 3 T in vivo.

Authors:  Tao Gong; Xia Zhang; Xinhong Wei; Shuhui Yuan; Muhammad G Saleh; Yulu Song; Richard A Edden; Guangbin Wang
Journal:  Neurochem Int       Date:  2020-10-22       Impact factor: 3.921

5.  Skeletal muscle transcriptional networks linked to type I myofiber grouping in Parkinson's disease.

Authors:  Kaleen M Lavin; Stuart C Sealfon; Merry-Lynn N McDonald; Brandon M Roberts; Katarzyna Wilk; Venugopalan D Nair; Yongchao Ge; Preeti Lakshman Kumar; Samuel T Windham; Marcas M Bamman
Journal:  J Appl Physiol (1985)       Date:  2019-12-12

Review 6.  Motion correction in magnetic resonance spectroscopy.

Authors:  Muhammad G Saleh; Richard A E Edden; Linda Chang; Thomas Ernst
Journal:  Magn Reson Med       Date:  2020-04-17       Impact factor: 3.737

7.  GABAergic changes in the thalamocortical circuit in Parkinson's disease.

Authors:  Annelies J M van Nuland; Hanneke E M den Ouden; Heidemarie Zach; Michiel F M Dirkx; Jack J A van Asten; Tom W J Scheenen; Ivan Toni; Roshan Cools; Rick C Helmich
Journal:  Hum Brain Mapp       Date:  2019-11-13       Impact factor: 5.038

8.  Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinson's Disease.

Authors:  Beate Pesch; Swaantje Casjens; Dirk Woitalla; Shalmali Dharmadhikari; David A Edmondson; Maria Angela Samis Zella; Martin Lehnert; Anne Lotz; Lennard Herrmann; Siegfried Muhlack; Peter Kraus; Chien-Lin Yeh; Benjamin Glaubitz; Tobias Schmidt-Wilcke; Ralf Gold; Christoph van Thriel; Thomas Brüning; Lars Tönges; Ulrike Dydak
Journal:  Cells       Date:  2019-01-29       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.